12 results
10-K
2022 FY
COYA
Coya Therapeutics Inc
29 Mar 23
Annual report
4:08pm
Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond … , targets for different neurodegenerative and auto immune diseases may require changes to our cell manufacturing platform, which may slow down
424B4
COYA
Coya Therapeutics Inc
30 Dec 22
Prospectus supplement with pricing info
4:17pm
technical, financial and human resources, whether or not any product candidates are ultimately identified. In addition, targets for different … . Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date
S-1/A
EX-10.1
COYA
Coya Therapeutics Inc
5 Dec 22
IPO registration (amended)
8:16am
) operating income; (xv) operating income after taxes; (xvi) pre-tax profit; (xvii) sales or revenue targets; (xviii) increases in revenue or components
S-1/A
15n k7ibjs
5 Dec 22
IPO registration (amended)
8:16am
S-1/A
EX-10.7
7qw1q amzoya
5 Dec 22
IPO registration (amended)
8:16am
S-1
EX-10.7
jtfje
18 Nov 22
IPO registration
5:06pm
S-1
yr6 z32m6hjsou7
18 Nov 22
IPO registration
5:06pm
DRS/A
saueogng uvy8pxg
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
zuhs3at
7 Oct 22
Draft registration statement (amended)
12:00am
DRS
jfve6f8 ubc320o
19 Aug 22
Draft registration statement
12:00am
- Prev
- 1
- Next